Separate from concerns about diversity, some experts and startups have questioned the idea that people should be asked to pay for genetic tests and reports about their health and ancestry from commercial companies. 23andMe, after all, benefits enormously from the genetic data that people pay $100 or more to share — and the scarcity of data from people from underrepresented groups makes their samples all the more valuable.